Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
利用双链 RNA (dsRNA) 反应和 PRC2 失活癌症的抗肿瘤作用
基本信息
- 批准号:10638759
- 负责人:
- 金额:$ 74.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-22 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:AllelesAntitumor ResponseAutophagocytosisBiochemicalC57BL/6 MouseCancer ModelCellsChromatin StructureClinical TrialsComplexDNA Modification MethylasesDataDecitabineDevelopmentDouble-Stranded RNAEZH2 geneEngineeringEngraftmentEvaluationEvolutionFutureGenerationsGeneticGenetic TranscriptionGenomeGoalsHigh PrevalenceHistone H3IRF3 geneImmuneImmune responseImmunocompetentImmunologic CytotoxicityImmunotherapyIn VitroIndividualInfectionInnate Immune ResponseLysineMalignant NeoplasmsMammary NeoplasmsMediatingModelingMolecularMusNF-kappa BNeurofibrosarcomaOutcomePhenotypePolycombRecombinant modified vaccinia virus AnkaraResistanceRetrotransposonRoleSignal PathwaySignal TransductionSoft tissue sarcomaSystemTherapeuticTranscriptional ActivationTumor Suppressor ProteinsVirusWorkantitumor effectbiomarker drivencancer cellcancer typecytotoxiccytotoxicitydemethylationdesigneffective therapyepigenomehistone methylationimmune checkpoint blockadeimmunogenicimmunogenicityimproved outcomein vivoinhibitorinnovationinsightknock-downmelanomamouse modelmultiple omicsneoplastic cellnovelnovel therapeutic interventionpre-clinicalresponsesensorsingle-cell RNA sequencingstemnessstress granuletranscriptometreatment effecttumortumor growthtumor heterogeneitytumor microenvironment
项目摘要
PROJECT SUMMARY/ABSTRACT:
The polycomb repressive complex 2 (PRC2) complex establishes and maintains di- and tri-methylation of the
histone H3 at lysine 27 (H3K27me2/3) in the genome and regulates chromatin structure, transcription, cellular
stemness and differentiation. PRC2 is a context-dependent tumor suppressor whose core components (e.g.,
EZH2, EED, or SUZ12) are inactivated in various cancer types. Among these, high-grade malignant peripheral
nerve sheath tumor (MPNST), an aggressive soft tissue sarcoma with no effective therapies, has a high
prevalence (≥80%) of biallelic inactivation of EED or SUZ12, leading to complete loss of the PRC2 function.
PRC2 loss in cancer results in aberrant transcriptional activation of developmentally silenced master regulators,
which leads to enhanced cellular plasticity and aberrant activation of multiple signaling pathways. We recently
uncovered that PRC2 loss in cancer leads to an immune-desert tumor microenvironment and resistance to
immune checkpoint blockade. Nevertheless, we observed that, in murine models of PRC2-loss MPNST and
mammary tumors, response to immunotherapy can be enhanced by infection with immunogenic virus, which
activates double-stranded RNA (dsRNA) signaling responses. Moreover, we have identified and validated a
lethal interaction between PRC2 loss and DNA methyltransferase 1 (DNMT1) knockdown in MPNST. In vitro and
in vivo treatment with a demethylating agent (decitabine) or selective DNMT1 inhibitors (GSK862, GSK032) led
to enhanced cytotoxicity and antitumor effects in PRC2-loss compared to PRC2 wild-type (wt) MPNST models.
Mechanistically, DNMT inhibitor (DNMTi) treatment in the PRC2-loss context amplified the expression of
endogenous retrotransposons and subsequently led to activation of innate immune responses, which could be
explained by retrotransposons forming dsRNA and triggering cytotoxicity via PKR-dependent dsRNA sensing.
we hypothesize that PRC2 loss in cancer may create therapeutic opportunities for agents (e.g., DNMTi, synthetic
dsRNA, immunogenic viruses) that activate the dsRNA signaling pathways in tumor cells to induce cytotoxicity
and enhance immunogenicity. Here, we propose integrative multi-omics analysis (e.g., transcriptome,
epigenome, single-cell [sc]RNA-seq and scATAC-seq) and innovative approaches (e.g., novel immunogenic
viruses, a novel lineage-tracking system) to evaluate novel therapeutic strategies and their mechanisms of
activating dsRNA responses and anti-tumor effects in relevant PRC2-loss cancers, focusing on specific aims:
(1) dissect the molecular mechanisms that underlie the selective sensitivity to DNMTi in different PRC2-loss
cancers; (2) evaluate exogenous dsRNAs as a strategy to induce cytotoxicity in PRC2-loss tumors; and (3)
evaluate novel therapeutic strategies of activating dsRNA-responses in relevant cancer models. These studies
will generate insights into exploiting dsRNA-sensing and activation of innate immune responses as therapeutic
strategies in PRC2-loss cancers and provide the pivotal preclinical data for biomarker-driven clinical trials.
项目总结/文摘:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ping Chi其他文献
Ping Chi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ping Chi', 18)}}的其他基金
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
ASTX727 在 PRC2 缺失恶性周围神经鞘瘤 (MPNST) 患者中的 II 期研究
- 批准号:
10502752 - 财政年份:2022
- 资助金额:
$ 74.5万 - 项目类别:
Phase II Study of ASTX727 in Patients with PRC2 loss Malignant Peripheral Nerve Sheath Tumor (MPNST)
ASTX727 在 PRC2 缺失恶性周围神经鞘瘤 (MPNST) 患者中的 II 期研究
- 批准号:
10707164 - 财政年份:2022
- 资助金额:
$ 74.5万 - 项目类别:
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)
了解和靶向 NF1 缺陷的恶性周围神经鞘瘤 (MPNST) 中的 MAPK 通路激活
- 批准号:
10376770 - 财政年份:2021
- 资助金额:
$ 74.5万 - 项目类别:
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)
了解和靶向 NF1 缺陷的恶性周围神经鞘瘤 (MPNST) 中的 MAPK 通路激活
- 批准号:
10657337 - 财政年份:2021
- 资助金额:
$ 74.5万 - 项目类别:
Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)
了解和靶向 NF1 缺陷的恶性周围神经鞘瘤 (MPNST) 中的 MAPK 通路激活
- 批准号:
10156866 - 财政年份:2021
- 资助金额:
$ 74.5万 - 项目类别:
Clinical Scholars Biomedical Research Training Program
临床学者生物医学研究培训计划
- 批准号:
10179325 - 财政年份:2019
- 资助金额:
$ 74.5万 - 项目类别:
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer
癌症中新型致癌 ALK 变体转录激活的表观遗传机制
- 批准号:
10394271 - 财政年份:2018
- 资助金额:
$ 74.5万 - 项目类别:
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer
癌症中新型致癌 ALK 变体转录激活的表观遗传机制
- 批准号:
10113559 - 财政年份:2018
- 资助金额:
$ 74.5万 - 项目类别:
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)
MEK162的2期试验
- 批准号:
9567835 - 财政年份:2017
- 资助金额:
$ 74.5万 - 项目类别:
Phase2 trial of MEK162 & imatinib combined therapy in GIST, IND119794(09/20/2013)
MEK162的2期试验
- 批准号:
9762575 - 财政年份:2017
- 资助金额:
$ 74.5万 - 项目类别:
相似海外基金
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
通过间质局部消融免疫疗法增强全身抗肿瘤反应,与转移性胰腺肿瘤的免疫检查点疗法协同作用
- 批准号:
10580071 - 财政年份:2022
- 资助金额:
$ 74.5万 - 项目类别:
Development of new cancer treatment utilizing the enhancement of antitumor response caused by allo reaction
利用同种异体反应增强抗肿瘤反应开发新的癌症治疗方法
- 批准号:
20K17649 - 财政年份:2020
- 资助金额:
$ 74.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of CD4 T cells and APCs in the induction and maintenance of an effective antitumor response
CD4 T 细胞和 APC 在诱导和维持有效抗肿瘤反应中的作用
- 批准号:
nhmrc : 143674 - 财政年份:2001
- 资助金额:
$ 74.5万 - 项目类别:
NHMRC Project Grants
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
- 批准号:
2377164 - 财政年份:1997
- 资助金额:
$ 74.5万 - 项目类别:
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
- 批准号:
2712876 - 财政年份:1997
- 资助金额:
$ 74.5万 - 项目类别:














{{item.name}}会员




